Zobrazeno 1 - 10
of 50
pro vyhledávání: '"K. L. Blackwell"'
Autor:
Jeremy Force, Kelly Marcom, Carey K. Anders, Kelly E. Westbrook, Grace R. Anderson, K. L. Blackwell, Sarah Sammons, C Yip, Kris C. Wood
Publikováno v:
Cancer Research. 79:P1-06
Background: Triple negative breast cancer (TNBC) remains a heterogeneous clinical phenotype with few, known therapeutic targets. PARP inhibitors (PARPi) are the first approved, targeted therapy in TNBC, limited to germline BRCA mutant (BRCAm) cancers
Autor:
Rebecca G. Bagley, Cynthia X. Ma, Yi He, J. Cortés, Andres Forero-Torres, V Moebus, Linda T. Vahdat, CD Turner, Abdel Halim, Melinda L. Telli, M. Melisko, Peter Schmid, G Wright, Esther Holgado, Alberto J. Montero, L Fehrenbacher, K. L. Blackwell, D. A. Yardley, Rita Nanda
Publikováno v:
Cancer Research. 79:P6-20
Background gpNMB is an internalizable transmembrane protein overexpressed in ˜40% of TNBC, and associated with a worse prognosis. Preclinical data implicates gpNMB in tumor invasion and metastasis. GV is a novel ADC designed to deliver monomethyl au
Autor:
Pierfranco Conte, H. A. Burris, JT Beck, K. L. Blackwell, K. Petrakova, Sibel Blau, M. Miller, M Monaco, Santosh Sutradhar, M. Campone, A.M. Favret, Shani Paluch-Shimon
Publikováno v:
Cancer Research. 78:P5-21
Background: In the Phase III MONALEESA-2 study (NCT01958021), ribociclib (RIB; cyclin-dependent kinase 4/6 inhibitor [CDK4/6i]) + letrozole (LET) significantly prolonged progression-free survival (PFS) vs placebo (PBO) + LET in postmenopausal women w
Autor:
K. L. Blackwell, Véronique Diéras, José Baselga, Silke Hoersch, Ian E. Krop, Luca Gianni, Manfred Welslau, Sunil Verma, David Miles, Marjorie C. Green, Jin Xu, Mark D. Pegram
Publikováno v:
The Lancet Oncology. 18:732-742
Summary Background The antibody–drug conjugate trastuzumab emtansine is indicated for the treatment of patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane. Approval of this drug was based on progres
Autor:
Grace Kim, K. L. Blackwell, Terry Hyslop, Bercedis Peterson, Jessica L. Narloch, John P. Kirkpatrick, Peter E. Fecci, K Harnden, Gloria Broadwater
Publikováno v:
Cancer Research. 77:P5-08
BACKGROUND: Brain metastasis is a complication in advanced breast cancer (ABC) and is associated with poor prognosis. Incidence of breast cancer brain metastasis (BCBM) is increasing with advances in therapy, allowing patients to survive long enough
Autor:
M. Miller, Arlene Chan, Emilio Alba, C. Germa, K. L. Blackwell, H. A. Burris, Wolfgang Janni, A.M. Favret, Sunil Verma, Samit Hirawat, Olga Burdaeva, S. Mondal, M. Campone, Y-S Yap, EP Winer
Publikováno v:
Cancer Research. 77:P4-22
Background: Patients with ABC who present with visceral metastases have a worse outcome than patients with non-visceral disease, while patients with bone-only disease tend to have a better prognosis. Ribociclib (LEE011) is an oral, selective inhibito
Autor:
S. Verma, B Kang, David Miles, J Xu, Ian E. Krop, Mark D. Pegram, Manfred Welslau, Marjorie C. Green, L. Gianni, J. Baselga, K. L. Blackwell, Véronique Diéras
Publikováno v:
Cancer Research. 76:P4-14
Introduction T-DM1 is indicated for the treatment of advanced HER2-positive MBC in patients who previously received trastuzumab and a taxane (separately or in combination) based on data from the phase 3 EMILIA study (BO21977/TDM4370g; NCT00829166). I
Autor:
Paul K. Marcom, S Hwang, Kent J. Weinhold, Gloria Broadwater, Jeremy Force, Terry Hyslop, Edgardo R. Parrilla Castellar, Smita K. Nair, Sara Abbott, Kelly E. Westbrook, K. L. Blackwell, Noah D. Kauff, Ilona Stashko, Gretchen Kimmick
Publikováno v:
Cancer Research. 77:P2-04
Background: Increased stromal tumor infiltrating lymphocytes (TILs) are predictive and prognostic for improved outcomes from neoadjuvant or adjuvant chemotherapy in triple negative breast cancer. Increased tumor mutational burden may promote neoantig
Autor:
Linda T. Vahdat, Rebecca G. Bagley, Cynthia X. Ma, Yi He, Andres Forero, K Vance, G. Ouellette, G Wright, T Guthrie, Cristiano Ferrario, M. Melisko, Jie Zhang, M Seiler, Alberto J. Montero, L Fehrenbacher, K. L. Blackwell, D. A. Yardley, Rita Nanda, Brooke R. Daniel, H Chew
Publikováno v:
Cancer Research. 76:OT1-03
Background Glycoprotein NMB (gpNMB) is an internalizable transmembrane protein overexpressed in approximately 20% of breast cancer (BC), including approximately 40% of TNBC. gpNMB is a poor prognostic marker in BC (Rose CCR 2010) and preclinically ha
Autor:
Patrick Neven, Fabrice Andre, Luciano Latini, K. L. Blackwell, Antonino Musolino, Yunyu Zhang, S. Deudon, Matthew Squires, Carlos Barrios, J. Cortes, M. Campone, S Gogov
Publikováno v:
Cancer Research. 73:OT2-6
Background: Overcoming endocrine resistance is a critical goal in the treatment of HR+ breast cancer. Emerging in vitro evidence suggests that amplification and overexpression of fibroblast growth factor receptor 1 (FGFR1) is associated with endocrin